Approval
UK extends Joenja to APDS patients as young as four
The MHRA extended Pharming Group's leniolisib to children with activated PI3K delta syndrome who weigh 27 kg or more, making it the first UK therapy aimed at this young group. The label adds twice-daily 40 mg and 50 mg doses. Pharming expects children to gain access in February 2027 and will work with the NHS on supply.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.